7 Best Peptides for Retinal Health

What to Know Before Choosing a Peptide for Retinal Health

Retinal health is one of the more complex goals in the peptide space, and the landscape reflects that complexity. Some of these compounds have been studied in randomized controlled trials. Others are research chemicals with no human data at all. A few occupy a middle ground, used clinically in Russia and Eastern Europe with a published literature most Western practitioners have never encountered. Every one of them earns a place here for the same reason: people are using or actively discussing using them for retinal conditions. Evidence strength is stated honestly inside each entry rather than used as a filter for whether a compound makes the list.

No peptide is currently FDA-approved specifically for retinal health in the general sense, meaning dry age-related macular degeneration, retinitis pigmentosa, or general photoreceptor protection. That is the honest starting point. The conditions these compounds target are serious, often progressive, and in many cases have no approved disease-modifying therapy at all, which is precisely why the research and community interest is so active. Some people pursuing these compounds are doing so because conventional medicine has limited options for their condition.

These seven entries are numbered by how prominently each compound appears in research and real-world use for retinal goals. That ordering reflects depth of evidence and breadth of discussion, not a verdict that the first compound is better for you than the seventh. The right choice depends on your specific condition, your health history, and what you build with MyPeptidePal. Before starting any protocol for a serious retinal condition, consult a qualified ophthalmologist or retinal specialist.

1. Visoluten: The Khavinson Bioregulator for Retinal Tissue

Visoluten belongs to the Khavinson bioregulator system, a class of short peptides developed through decades of research in Russia and Eastern Europe. The core concept behind this system is tissue specificity: each bioregulator is designed to act on a particular tissue type by binding to gene promoter regions and epigenetically regulating the proteins that drive cell differentiation and survival. For retinal tissue specifically, Visoluten targets retinal neurons and retinal pigment epithelium cells, the layer of cells beneath the photoreceptors that is critical to their function and long-term survival.

The proposed mechanism starts at the gene level. Short peptides bind directly to promoter regions in retinal tissue, regulating the synthesis of protein markers needed for differentiation of retinal neurons and RPE cells. The downstream effects include suppression of programmed cell death in pigment epithelium cells and stimulation of the retinal neuroreceptor system. Studies on closely related Khavinson tetrapeptides have shown restoration of the inner nuclear layer and pigment epithelium by upregulating these differentiation markers, with work published in the Bulletin of Experimental Biology and Medicine and Cell Biochemistry and Function, including publications by Khavinson and Trofimova (2019) and Khavinson and Pronyaeva (2014).

The evidence base for Visoluten is predominantly preclinical, drawing on animal models and cell culture work rather than large randomized trials. Visoluten and its close relatives, Retinalamin and Retilanamin, are used clinically in Russia and Eastern Europe for macular degeneration and retinal degeneration, and that clinical use is real and longstanding. What does not exist as of 2026 is a published peer-reviewed Western human clinical trial confirming efficacy by the standards most practitioners in the US or EU would recognize. Community discussion in forums focused on macular degeneration reflects genuine interest, particularly from people who have exhausted conventional options and are aware of the Russian literature.

Visoluten is available in some Western markets as a research chemical or dietary supplement but is not FDA-approved and has no active Western clinical trial registration. People pursuing it outside Russia and Eastern Europe are doing so based on the Russian literature and community-reported interest. If you are drawn to the Khavinson approach, Visoluten and Retinalamin represent the most retina-specific options within that system.

2. Elamipretide: The Mitochondria-Targeting Compound With Human Trial Data

Elamipretide, also known as SS-31 or MTP-131, is a synthetic aromatic-cationic tetrapeptide with a specific and well-characterized target: the inner mitochondrial membrane. Photoreceptors are among the most metabolically demanding cells in the body, and their dependence on healthy mitochondrial function makes them unusually vulnerable to the mitochondrial decline that comes with age. Elamipretide is designed to work precisely where that vulnerability lives.

The mechanism centers on cardiolipin, a lipid found almost exclusively in the inner mitochondrial membrane. Elamipretide binds selectively to cardiolipin and alters the biophysical properties of the membrane in ways that promote efficient electron transfer through the electron transport chain. Think of it as stabilizing the power plant at the heart of each photoreceptor cell so it generates less damaging waste while producing more usable energy. The practical effect is reduced oxidative stress in photoreceptors. Published peer-reviewed work describes this mechanism and its effects on age-related visual function, finding that the compound selectively improves age-related loss of photopic visual function, meaning the cone-based daytime vision that degrades with AMD.

Elamipretide has completed Phase I and Phase II clinical trials for age-related macular degeneration, giving it the strongest human evidence base of any compound on this list for a retinal condition. The picture is not straightforward. A Phase 2 trial for AMD missed its primary endpoint, a finding widely reported and representing a genuine setback for the AMD indication specifically. A Phase 3 program was reportedly moving forward as of mid-2026. Separately, elamipretide holds FDA approval for Barth syndrome, a mitochondrial disease, which establishes a documented safety profile that most research peptides entirely lack.

People who pursue elamipretide for retinal health are using it off-label, either through compounding or specialist access. It is not a standard telehealth compound and is not widely available through typical research chemical channels. The human data puts it in a different category from most compounds on this list, even with the Phase 2 AMD setback. The mitochondrial mechanism is well-evidenced, and whether it can translate into clinical benefit for AMD remains a genuinely open question that ongoing trials are designed to answer.

3. AXT107 and ALG-1001: Integrin Peptides With Published Visual Outcomes

AXT107 and its earlier iteration ALG-1001 are synthetic integrin-binding peptides, and they hold a distinction no other compound in this article can claim: published human efficacy data showing meaningful visual improvement in people with a retinal disease.

The mechanism is distinct from anti-VEGF therapy, the current standard of care for wet age-related macular degeneration and diabetic macular edema. Rather than blocking vascular endothelial growth factor directly, integrin peptides block the angiogenic cascade further upstream by binding integrin receptor sites that pathological blood vessels depend on for growth. Think of integrins as the anchoring system that lets new, unwanted blood vessels establish themselves in the retina. Blocking that anchor stops the cascade without touching VEGF directly, which matters because some patients stop responding to anti-VEGF injections over time.

The published human data comes from a Phase 1 study of ALG-1001 in 15 subjects with diabetic macular edema. Fifty-three percent of participants showed a reduction in central macular thickness of 30 to 80 percent. Eight subjects improved visual acuity by three to five lines on the chart. Four patients moved from legally blind to functional vision. Benefits lasted at least three months after treatment ended, with no serious adverse events reported. Those are striking results for a small Phase 1 study, and they are the central reason integrin peptides sit near the top of this list. AXT107 is the current iteration, with a Phase 1b/2a study in wet AMD enrolling as of the research date.

These compounds are administered as intravitreal injections, meaning injected directly into the vitreous cavity of the eye by a specialist. They are investigational, not FDA-approved, and their real-world use outside clinical trials is limited. The published human data, however, places them among the most evidence-supported peptide candidates in the entire retinal space.

4. PEDF-Derived Peptides: The Eye-Drop Approach to Photoreceptor Protection

Pigment epithelium-derived factor, or PEDF, is a protein naturally produced in the eye that plays a central role in photoreceptor survival. Researchers at the NIH developed synthetic peptide fragments derived from PEDF, with the variants H105A and 17-mer representing the most studied candidates. What sets this work apart from most retinal peptide research is the delivery method: these fragments are designed specifically to be administered as eye drops, penetrating the retina after topical ocular application without requiring an injection into the eye.

The mechanism targets a specific failure point in degenerating photoreceptors. Retinal degeneration in conditions like retinitis pigmentosa involves calcium overload inside photoreceptor cells, a process that triggers cell death. PEDF-derived peptides bind to the PEDF receptor on retinal cells and activate its phospholipase activity, which mitigates that calcium overload and interrupts the apoptotic cascade. The anti-angiogenic properties of PEDF carry over to the fragments as well, potentially making them relevant to both degenerative and neovascular conditions.

In mouse models of retinitis pigmentosa, H105A and the 17-mer effectively delayed degeneration and preserved retinal structure, particularly in the more vulnerable regions of the retina, with no toxicity or side effects observed. The step beyond animal work came from experiments using human retinal organoids, lab-grown tissue derived from human cells, where the peptides protected photoreceptors from oxidative stress. A 2025 publication in Nature and a 2024 preprint describe this data. An active clinical trial is evaluating a novel peptide-based therapy for retinal dystrophies and AMD, with results not yet published as of mid-2026.

The evidence here sits at an advanced preclinical stage, stronger than animal-only data because of the human tissue results, but not yet confirmed in a published human clinical trial. The non-invasive delivery route and the NIH research backing make PEDF-derived peptides one of the more closely watched early-stage candidates in the field.

5. BPC-157: The Broadly Used Tissue Repair Peptide

BPC-157, or Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. It is one of the most widely discussed compounds in the biohacking community for general tissue repair and cytoprotection, and it appears in discussions about retinal health largely as an extension of that broader reputation rather than because of deep retina-specific research.

The mechanisms most relevant to retinal applications involve vascular support and cell survival signaling. BPC-157 increases expression of vascular endothelial growth factor and activates the PI3K/Akt cell survival pathway, which inhibits apoptosis and promotes tissue recovery. It also increases nitric oxide synthase activity, causing vasodilation and improving blood flow. In the retinal context, these effects translate to potential support for ischemic or damaged retinal tissue, where restored circulation and reduced cell death are meaningful goals.

The retinal-specific evidence for BPC-157 is preclinical. Rodent studies have shown retinal support in diabetic mouse models, and community sources point to its reputation for promoting angiogenesis and reducing inflammation in vascular tissue. No human ocular clinical trials have been published for BPC-157 as of 2026. What exists in the retinal space is animal data plus user-reported experience from the biohacking community, where it is discussed for conditions including glaucoma, retinal injury recovery, and diabetic retinopathy. The broader BPC-157 literature for gastrointestinal and musculoskeletal applications is substantially larger, and that is where most of the human-adjacent experience base originates.

BPC-157 is on the FDA's Category 2 bulk substance list, making it ineligible for compounding by pharmacies for human use, and it is sold as a research chemical in most Western markets. People using it for retinal support are doing so without a standard clinical pathway. The interest is real and the biological rationale is plausible, but the human data for this specific application does not yet exist.

6. Semax: Neuroprotection for the Inner Retina

Semax is a synthetic heptapeptide that functions as an analog of a fragment of adrenocorticotropic hormone. Developed in Russia and approved there for neuroprotective indications, its primary route of action in the nervous system involves boosting levels of brain-derived neurotrophic factor, or BDNF, a protein that promotes the survival and function of neurons. In the retinal context, the cells most relevant to this mechanism are retinal ganglion cells, the neurons that form the optic nerve and carry visual information from the eye to the brain.

Retinal ganglion cell loss is the defining feature of glaucoma, and it is also a component of optic neuritis and other conditions where the inner retina comes under stress. Semax acts through the TrkB receptor, which is BDNF's primary receptor, activating the PI3K/Akt neuroprotection pathway downstream. Rodent glaucoma models have shown neuroprotective effects through this mechanism, and the BDNF-TrkB pathway itself is one of the better-characterized neuroprotective cascades in retinal biology.

Semax is not FDA-approved in the United States and holds research chemical status in most Western markets. Users in the biohacking community typically use it as a nasal spray, and some interest has developed around its potential for ocular applications given the ganglion cell connection. The evidence for retinal use specifically remains at the preclinical level for Western audiences, with the human data coming from its approved neuroprotective indications in Russia rather than from ophthalmology trials. For people focused specifically on glaucoma or optic nerve conditions, the BDNF mechanism gives Semax a more targeted rationale than several other entries on this list.

7. Epitalon: The Longevity Peptide With Retinal Interest

Epitalon is a synthetic tetrapeptide developed within the Khavinson bioregulator system, sharing the same Russian research lineage as Visoluten. Unlike Visoluten, which was developed specifically for retinal tissue, Epitalon is a broader longevity and anti-aging compound whose retinal interest comes largely from its systemic effects on oxidative stress and aging biology rather than tissue-specific design.

The compound activates telomerase, the enzyme that maintains telomere length and is associated with cellular longevity. It also modulates the melatonin pathway, which carries its own antioxidant and circadian implications for retinal tissue, since the retina has its own melatonin-producing cells and melatonin plays a documented role in photoreceptor protection. In rodent aging models, Epitalon has been shown to reduce retinal oxidative stress, one of the upstream drivers of photoreceptor and RPE damage in age-related conditions.

The human evidence for Epitalon's retinal effects is limited. There is some clinical data in the Russian literature, primarily from the same research group that developed it, but no published randomized controlled trials for retinal conditions from Western-standard sources as of 2026. In community discussions, people with retinitis pigmentosa have reported using Epitalon alongside other interventions, with at least one account noting improved visual scores, though these are single-case anecdotal reports without a control. The compound is available as a research chemical and is not FDA-approved.

Epitalon's position on this list reflects that its retinal interest is more indirect than Visoluten's, arriving through systemic anti-aging properties rather than tissue-specific design. For someone already drawn to the Khavinson system or to longevity-oriented approaches to retinal aging, Epitalon is a compound that comes up in the conversation, and that is the honest basis for its inclusion here.

How These Peptides Compare

Frequently Asked Questions

Are Any of These Peptides FDA-Approved for Retinal Conditions?

No peptide is currently FDA-approved specifically for retinal health in the general sense, covering conditions like dry age-related macular degeneration, retinitis pigmentosa, or general photoreceptor protection. Elamipretide holds FDA approval for Barth syndrome, a mitochondrial disease in a different clinical context, and GLP-1 receptor agonists are FDA-approved for diabetes and obesity with retinal protection studied as a secondary effect in diabetic patients. Every other compound on this list is either investigational, approved only in countries such as Russia, or sold as a research chemical.

How Do These Peptides Reach the Retina?

Delivery method varies considerably across these compounds and matters greatly for whether a peptide can actually reach retinal tissue in meaningful concentrations. PEDF-derived peptides are specifically designed as eye drops that penetrate ocular tissue topically after application. AXT107 and ALG-1001 are administered as intravitreal injections directly into the eye by a specialist. Systemic compounds like BPC-157, Visoluten, Elamipretide, Semax, and Epitalon reach the retina through the bloodstream after subcutaneous injection, relying on their ability to cross or bypass the blood-retina barrier in sufficient concentration to have an effect.

Is the Evidence Strong Enough to Use These Compounds for Serious Eye Conditions?

The evidence varies dramatically depending on the compound, and that variation is the honest answer. AXT107 and ALG-1001 have published human data showing real visual improvement in diabetic macular edema. Elamipretide has completed human trials for AMD with mixed results. Most others on this list are at the preclinical stage for retinal applications, or draw on community-reported experience without controlled human data. For a serious, progressive retinal condition, the decision to pursue any of these compounds should involve a retinal specialist who can weigh the evidence against your specific situation.

What Is the Khavinson Bioregulator System?

The Khavinson system is a framework developed by Russian researcher Vladimir Khavinson built around the idea that short peptide sequences derived from specific tissues can act as tissue-specific bioregulators, binding to gene promoters and restoring protein synthesis patterns associated with younger, healthier cells. Visoluten and Epitalon are both part of this system. The system has a substantial published literature, primarily in Russian-language journals and from Khavinson's own research group, covering a wide range of tissues including the retina. The evidence has not been independently replicated in large Western clinical trials, which is why these compounds occupy a different evidence tier from pharmaceutical candidates like elamipretide or AXT107, even though their clinical use in Russia extends back decades.

Can BPC-157 Help With Glaucoma?

BPC-157 generates genuine interest in the glaucoma conversation because of its established profile for tissue repair, vascular support, and neuroprotection in other contexts. The proposed mechanisms, including improved blood flow through nitric oxide signaling and cell survival through PI3K/Akt activation, are biologically plausible for glaucoma given that retinal ganglion cell loss involves both vascular and neurotrophic factors. No human clinical trial has evaluated BPC-157 for glaucoma as of 2026, and the retinal evidence base is limited to animal models. The biological rationale is there, but the human data to confirm it does not yet exist.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for retinal health in one place.